Nor UDCA

Life with Primary Sclerosing Cholangitis
1

I read that 24-norursodeoxycholic acid (Nor UDCA) performed well in phase 2 clinical trials for PSC and is now in phase three which will be completed early 2026. The company will then apply for FDA approval.

This is very positive and exciting news! What are your thoughts

1 Like
2

Not trying to be a party pooper but 15% “success” doesn’t seem to be a real breakthrough.